The simultaneous inhibition of ICOS and CD28 signaling, achieved through the use of inhibitors like Acazicolcept, has proven effective in reducing inflammation and slowing the progression of RA and psoriatic arthritis (PsA) [31]. Here, ICOS is linked to psoriatic arthritis.